Preclinical Evaluation of ZD1839 Alone or in Combination with Oxaliplatin in a Panel of Human Tumor Cell Lines – Implications for Clinical Use

Publisher： Karger

E-ISSN： 2296-5262|28|10|482-488

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.10, 2005-09, pp. : 482-488

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon-α Promotes the Anti-Proliferative Effect of Gefitinib (ZD1839) on Human Colon Cancer Cell Lines

By  

Oncology, Vol. 69, Iss. 3, 2005-10 ,pp. : 224-238

Karger

Access to resources Recommend Favorite

Evaluation of a Device for Negative Selection of CD34+ Cells Alone or in Combination with Breast Cancer Tumor Cell Purging

By  

Transfusion Medicine and Hemotherapy, Vol. 28, Iss. 2, 2001-04 ,pp. : 67-72

Karger

Access to resources Recommend Favorite

A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines

By Eriguchi M.   Nonaka Y.   Yanagie H.   Yoshizaki I.   Takeda Y.   Sekiguchi M.  

Biomedicine and Pharmacotherapy, Vol. 57, Iss. 9, 2003-11 ,pp. : 412-415

Elsevier

Access to resources Recommend Favorite

Antiangiogenic Effect of ZD1839 against Murine Renal Cell Carcinoma (RENCA) in an Orthotopic Mouse Model

By  

Urologia Internationalis, Vol. 75, Iss. 2, 2008-07 ,pp. : 159-166

Karger

Access to resources Recommend Favorite

Desmoplastic Small Round Cell Tumor: Report of 2 Cases Treated with Chemotherapy Alone or in Combination with Bevacizumab

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-02 ,pp. : 102-108

Karger

Access to resources Recommend Favorite